Diagnosis of liver cirrhosis by transit-time analysis at contrast-enhanced ultrasonography

Abbattista, T.; Ridolfi, F.; Ciabattoni, E.; Marini, Francesco; Bendia, E.; Brunelli, E.; Busilacchi, P

doi:10.1007/s11547-008-0292-3

Cited by 20 publications

(26 citation statements)

References 32 publications

(45 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study, the hepatic vein arrival time gradually decreased with the severity of fibrosis, as reported in the literature most based on the patients with chronic hepatitis C (Albrecht et al 1999;Hirota et al 2005;Lim et al 2006;Sugimoto et al 2002), but significant changes were found only when cirrhosis was present; the hepatic artery and portal vein arrival times were not significantly changed with the progress of liver fibrosis. In contrast, intrahepatic transit times (HA-HVTT and PV-HVTT) decreased with the progression of fibrosis, consistent with the literature (Pedersen et al 2005;Abbattista et al 2008;Staub et al 2009) and were significantly correlated with the stages of liver fibrosis. PV-HVTT even became a negative number in some cirrhotic patients.…”

Section: Discussionsupporting

confidence: 90%

Intrahepatic Transit Time Predicts Liver Fibrosis in Patients with Chronic Hepatitis B: Quantitative Assessment with Contrast-Enhanced Ultrasonography

Li¹,

Ding²,

Fan³

et al. 2010

Ultrasound in Medicine & Biology

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 90%

Intrahepatic Transit Time Predicts Liver Fibrosis in Patients with Chronic Hepatitis B: Quantitative Assessment with Contrast-Enhanced Ultrasonography

Li¹,

Ding²,

Fan³

et al. 2010

Ultrasound in Medicine & Biology

View full text Add to dashboard Cite

“…The titles and abstracts of these studies were reviewed; 170 were excluded based on the selection criteria, and 12 were ultimately identified as relevant to our review. Therefore, we analyzed these 12 studies13,26–36 and the 844 included patients, as shown in Table 1 and Fig. 1.…”

Section: Resultsmentioning

confidence: 99%

“…Seven studies used a Siemens Sequoia ultrasound system (Siemens Healthcare, Erlangen, Germany) 13,27,28,31–33,35. GE Logiq system (General Electric Healthcare, Milwaukee, WI, USA) was used in two of the studies,26,34 while a Toshiba system (Toshiba Corporation, Tokyo, Japan) was used in two other studies 29,30. With regard to contrast, there were five studies13,27,28,32,33 that used Levovist, the first-generation contrast agent.…”

Section: Resultsmentioning

confidence: 99%

Diagnostic Accuracy of Hepatic Vein Arrival Time Performed with Contrast-Enhanced Ultrasonography for Cirrhosis: A Systematic Review and Meta-Analysis

2017

View full text Add to dashboard Cite

Background/AimsWe identified reports in the literature regarding the diagnostic accuracy of hepatic vein arrival time (HVAT) measured by contrast-enhanced ultrasonography (CEUS) to assess hepatic fibrosis in cirrhosis.MethodsThe Ovid MEDLINE, Embase, and Cochrane databases were searched for all studies published up to 23 July 2015 that evaluated liver status using CEUS and liver biopsy (LB). The QUADAS-II (quality assessment of diagnostic accuracy studies-II) was applied to assess the internal validity of the diagnostic studies. Selected studies were subjected to a meta-analysis with MetaDisc 1.4 and RevMan 5.3.ResultsA total of 12 studies including 844 patients with chronic liver disease met our inclusion criteria. The overall summary sensitivity, specificity, positive likelihood ratio, and negative likelihood ratio of the HVAT measured by CEUS for the detection of cirrhosis compared to LB were 0.83 (95% confidence interval [CI], 0.77 to 0.89), 0.75 (95% CI, 0.69 to 0.79), 3.45 (95% CI, 1.60 to 7.43), and 0.28 (95% CI, 0.10 to 0.74), respectively. The summary diagnostic odds ratio (random effects model) was 15.23 (95% CI, 3.07 to 75.47), the summary receiver operator characteristics area under the curve was 0.74 (standard error [SE]=0.14), and the index Q was 0.69 (SE=0.11).ConclusionsBased on a systematic review, the measurement of HVAT by CEUS exhibited an increased accuracy and correlation for the detection of cirrhosis.

show abstract

“…A possible explanation may be the uptake or trapping of Levovist MBs in the sinusoids of the liver, that occurs until larger arterovenous shunting, typical of cirrhosis, has occurred [127]. Using Sonovue, the cut-off value to identify cirrhosis appeared shorter and namely 17 seconds, a value that showed excellent sensitivity and specificity [128,129]. However, the case series was small and the data have not been replicated in further centres so far.…”

Section: Hepatic Vein Transit Time (Hvtt)mentioning

confidence: 96%

Contrast-enhanced Ultrasound for Liver Imaging: Recent Advances

Salvatore

Borghi²,

Piscaglia³

2012

CPD

View full text Add to dashboard Cite

Contrast-enhanced ultrasonography (CEUS), providing relevant informations not available with non-enhanced ultrasonography, greatly impacted the practice of liver imaging. The characterization of focal liver lesions (FLLs), is obtained in a rapid, accurate and safe way and is considered the main hepatic indication; however CEUS offers other established or emergent relevant applications. Metastases detection and assessment of response to locoregional tumor treatment are accepted applications with specific indications. Needle guidance in case of poorly or non visible target lesions at conventional ultrasound is also accepted. The early assessment of response to systemic treatment, and in particular to antiangiogenic ones, by quantification software is an emergent application. The manageability of CEUS determined also its use in the operating theatre, improving the accuracy of intraoperatory US with a significant impact on final surgical strategy. In cirrhotic patients, the role of CEUS was proven highly accurate and sensitive in the characterization of portal vein thrombosis, by identification of contrast arterial enhancement inside the thrombus, that occurs only in case of neoplastic origin. In recent years microbubbles taken up by Kupffer cells, thus possessing a "postvascular" phase, were registered as ultrasound contrast agent in Japan (Sonazoid). During the post-vascular phase tumoral tissue tend to appear as a contrast defect image due to the lack of Kupffer cells, strongly contributing to tumor staging beside characterization. Newly developed techniques, such as fusion imaging or real-time three dimensional US, in addition to other applications of CEUS, in terms of post-transplantation or cholecystitis-related complications, have been recently proposed and will be discussed.

show abstract

Diagnosis of liver cirrhosis by transit-time analysis at contrast-enhanced ultrasonography

Abstract: Analysis of the time of onset of US contrast enhancement of the hepatic vein appears to be a potentially useful noninvasive supplement to conventional sonography and Doppler in the follow-up of patients with chronic diffuse liver disease.

Cited by 20 publications

References 32 publications

Intrahepatic Transit Time Predicts Liver Fibrosis in Patients with Chronic Hepatitis B: Quantitative Assessment with Contrast-Enhanced Ultrasonography

Intrahepatic Transit Time Predicts Liver Fibrosis in Patients with Chronic Hepatitis B: Quantitative Assessment with Contrast-Enhanced Ultrasonography

Diagnostic Accuracy of Hepatic Vein Arrival Time Performed with Contrast-Enhanced Ultrasonography for Cirrhosis: A Systematic Review and Meta-Analysis

Contrast-enhanced Ultrasound for Liver Imaging: Recent Advances

Contact Info

Product

Resources

About